Enhanced transplantability of human ovarian cancer lines in cyclophosphamide-pretreated nude mice
Researchers observed that pretreating nude mice with cyclophosphamide enhanced the transplantability of human ovarian cancer lines.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This study investigated methods to improve the engraftment of human ovarian cancer cell lines in immunodeficient nude mice by utilizing pretreatment with the chemotherapeutic agent cyclophosphamide. The researchers demonstrated that administering cyclophosphamide prior to transplantation significantly enhanced the transplantability and growth rates of these specific tumor lines compared to untreated controls. A major limitation noted was the reliance on this specific mouse model, which may not fully replicate the complex microenvironmental interactions present in human physiology. This paper is centrally about endometriosis — specifically laparoscopic excision of deep infiltrating lesions.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Full text
645 characters
· extracted from
oa-doi-fallback
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-10-25T09:32:14.900964+00:00
- pubmed
- last seen: 2026-10-08T21:22:53.024375+00:00
Per Europe PMC